Suchergebnisse - "Wall, Jaclyn A"

PubPharm (13)

1

Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers

enthalten in: Gynecologic oncology | 2024

von Pozzar, R. | Wall, J. | Tavormina, A. | +6

2

Patient Portal Use Among Family Caregivers of Individuals With Dementia and Cancer : Regression Analysis From the National Study of Caregiving

enthalten in: JMIR aging | 2023

von Bratches, R. | Wall, J. | Puga, F. | +5

3

Navigating job and cancer demands during treatment : A qualitative study of ovarian cancer patients

enthalten in: Gynecologic oncology | 2022

von Liang, M. | Simons, J. | Herbey, I. | +5

4

Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management

enthalten in: Gynecologic oncology | 2022

von Wall, J. | Lipking, K. | Smith, H. | +3

5

Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer : Results from a prospective cohort study

enthalten in: Gynecologic oncology | 2021

von Arend, R. | Goel, N. | Roane, B. | +6

6

Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance

enthalten in: Molecular cancer therapeutics | 2021

von Goel, N. | Foxall, M. | Scalise, C. | +2

7

Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774

enthalten in: Gynecologic oncology | 2020

von Betella, I. | Turbitt, W. | Szul, T. | +7

ErratumFor: Gynecol Oncol. 2020 Jun;157(3):765-774. - PMID 32192732

8

The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer

enthalten in: Expert opinion on investigational drugs | 2020

von Wall, J. | Klempner, S. | Arend, R.

9

Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer

enthalten in: Annals of translational medicine | 2020

von Wall, J. | Arend, R.

CommentOn: Gynecol Oncol. 2019 Aug;154(2):294-301. - PMID 31174889

10

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

enthalten in: Gynecologic oncology | 2020

von Arend, R. | Beer, H. | Cohen, Y. | +8

CommentIn: Nat Rev Clin Oncol. 2020 Jul;17(7):391. - PMID 32300193